Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Emma Guttman

Showing results (341-350 of 387) with videos related to

Pageof 39
Sort By:
Journal of the American Academy of Dermatology|May 27, 2021
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvementCelina Dubin, Jacob W Glickman, Ester Del Duca, et al.
The Journal of Infectious Diseases|December 11, 2014
Whole-Genome Sequencing Identifies STAT4 as a Putative Susceptibility Gene in Classic Kaposi SarcomaMervi Aavikko, Eevi Kaasinen, Janne K Nieminen, et al.
Allergy|March 7, 2026
The OX40/OX40L Axis Promotes Th2 Activity and Impairs Regulatory T Cell Function in Atopic DermatitisKazuhiko Yamamura, Dante Dahabreh, Ester Del Duca, et al.
Experimental Dermatology|June 16, 2016
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitisSaakshi Khattri, Patrick M Brunner, Sandra Garcet, et al.
American Journal of Clinical Dermatology|December 12, 2019
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical TrialAmy S Paller, Ashish Bansal, Eric L Simpson, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 11, 2021
Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patientsClaudia C V Lang, Yael Renert-Yuval, Ester Del Duca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2023
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitisYael Renert-Yuval, Ester Del Duca, Bernd Arents, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Allergy|December 18, 2023
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, et al.
JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.
Pageof 39

Showing results (341-350 of 387) with videos related to

Sort By:
Pageof 39
Journal of the American Academy of Dermatology|May 27, 2021
Scalp and serum profiling of frontal fibrosing alopecia reveals scalp immune and fibrosis dysregulation with no systemic involvementCelina Dubin, Jacob W Glickman, Ester Del Duca, et al.
The Journal of Infectious Diseases|December 11, 2014
Whole-Genome Sequencing Identifies STAT4 as a Putative Susceptibility Gene in Classic Kaposi SarcomaMervi Aavikko, Eevi Kaasinen, Janne K Nieminen, et al.
Allergy|March 7, 2026
The OX40/OX40L Axis Promotes Th2 Activity and Impairs Regulatory T Cell Function in Atopic DermatitisKazuhiko Yamamura, Dante Dahabreh, Ester Del Duca, et al.
Experimental Dermatology|June 16, 2016
Efficacy and safety of ustekinumab treatment in adults with moderate-to-severe atopic dermatitisSaakshi Khattri, Patrick M Brunner, Sandra Garcet, et al.
American Journal of Clinical Dermatology|December 12, 2019
Clinically Meaningful Responses to Dupilumab in Adolescents with Uncontrolled Moderate-to-Severe Atopic Dermatitis: Post-hoc Analyses from a Randomized Clinical TrialAmy S Paller, Ashish Bansal, Eric L Simpson, et al.
Annals of Allergy, Asthma & Immunology : Official Publication of the American College of Allergy, Asthma, & Immunology|May 11, 2021
Immune and barrier characterization of atopic dermatitis skin phenotype in Tanzanian patientsClaudia C V Lang, Yael Renert-Yuval, Ester Del Duca, et al.
Journal of the European Academy of Dermatology and Venereology : JEADV|September 13, 2023
Treat-to-target in dermatology: A scoping review and International Eczema Council survey on the approach in atopic dermatitisYael Renert-Yuval, Ester Del Duca, Bernd Arents, et al.
Journal of the American Academy of Dermatology|January 22, 2018
Efficacy and safety of fezakinumab (an IL-22 monoclonal antibody) in adults with moderate-to-severe atopic dermatitis inadequately controlled by conventional treatments: A randomized, double-blind, phase 2a trialEmma Guttman-Yassky, Patrick M Brunner, Avidan U Neumann, et al.
Allergy|December 18, 2023
Effect of abrocitinib on skin biomarkers in patients with moderate-to-severe atopic dermatitisEmma Guttman-Yassky, Paola Facheris, Pedro Jesus Gomez-Arias, et al.
JAMA Dermatology|March 9, 2022
Efficacy and Safety of Upadacitinib in Patients With Moderate to Severe Atopic Dermatitis: Analysis of Follow-up Data From the Measure Up 1 and Measure Up 2 Randomized Clinical TrialsEric L Simpson, Kim A Papp, Andrew Blauvelt, et al.
Pageof 39